Cargando…

Open transcatheter valve implantation for mitral annular calcification: One-year outcomes

BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, Umar Imran, Gregg, Anne, Ball, Peter, Owens, Colum, Manoharan, Ganesh, Spence, Mark S., Jeganathan, Reuben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691218/
https://www.ncbi.nlm.nih.gov/pubmed/34977731
http://dx.doi.org/10.1016/j.xjtc.2021.08.004
_version_ 1784618761130606592
author Hamid, Umar Imran
Gregg, Anne
Ball, Peter
Owens, Colum
Manoharan, Ganesh
Spence, Mark S.
Jeganathan, Reuben
author_facet Hamid, Umar Imran
Gregg, Anne
Ball, Peter
Owens, Colum
Manoharan, Ganesh
Spence, Mark S.
Jeganathan, Reuben
author_sort Hamid, Umar Imran
collection PubMed
description BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI with severe mitral annular calcification and their procedural outcomes. METHODS: Retrospective analysis of patients from 2017 to 2020 referred for TMVI was carried out. Demographic characteristic details; surgical strategy; perioperative complications; and hospital stay, including 30-day and 1-year mortality, were analyzed. RESULTS: Eleven patients were referred for consideration of TMVI. The 8 patients who underwent TMVI had a median age of 74 years (range, 57-80 years), the median Society of Thoracic Surgeons score was 4.6 (range, 2.4-10.9), and European System for Cardiac Operative Risk Evaluation II score was 5.2% (2%-10.1%). The median cardiopulmonary bypass time and crossclamp times were 170 minutes (range, 150-248 minutes) and 152 minutes (range, 118-214 minutes), respectively. The median hospital stay was 29 days (range, 2-40 days). Thirty-day in hospital mortality was 12%, whereas 1-year mortality was 25%. There was symptomatic improvement with downgrade of New York Heart Association functional class from III or IV to I or II. The 3 patients who were turned down had a median age of 73 years, median Society of Thoracic Surgeons score was 13.4, and median European System for Cardiac Operative Risk Evaluation II score was 5.72%. They were alive at 12 months follow-up from the date of surgical assessment; however, all with New York Heart Association functional class III or IV symptoms. CONCLUSIONS: We describe a series demonstrating the technical consideration and capability of transatrial TMVI to treat mitral annular calcification and native mitral valve disease. Our results are favorable when compared with TMVI global registry data for transseptal or transapical approach.
format Online
Article
Text
id pubmed-8691218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86912182021-12-30 Open transcatheter valve implantation for mitral annular calcification: One-year outcomes Hamid, Umar Imran Gregg, Anne Ball, Peter Owens, Colum Manoharan, Ganesh Spence, Mark S. Jeganathan, Reuben JTCVS Tech Adult: Mitral Valve: Evolving Technology BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI with severe mitral annular calcification and their procedural outcomes. METHODS: Retrospective analysis of patients from 2017 to 2020 referred for TMVI was carried out. Demographic characteristic details; surgical strategy; perioperative complications; and hospital stay, including 30-day and 1-year mortality, were analyzed. RESULTS: Eleven patients were referred for consideration of TMVI. The 8 patients who underwent TMVI had a median age of 74 years (range, 57-80 years), the median Society of Thoracic Surgeons score was 4.6 (range, 2.4-10.9), and European System for Cardiac Operative Risk Evaluation II score was 5.2% (2%-10.1%). The median cardiopulmonary bypass time and crossclamp times were 170 minutes (range, 150-248 minutes) and 152 minutes (range, 118-214 minutes), respectively. The median hospital stay was 29 days (range, 2-40 days). Thirty-day in hospital mortality was 12%, whereas 1-year mortality was 25%. There was symptomatic improvement with downgrade of New York Heart Association functional class from III or IV to I or II. The 3 patients who were turned down had a median age of 73 years, median Society of Thoracic Surgeons score was 13.4, and median European System for Cardiac Operative Risk Evaluation II score was 5.72%. They were alive at 12 months follow-up from the date of surgical assessment; however, all with New York Heart Association functional class III or IV symptoms. CONCLUSIONS: We describe a series demonstrating the technical consideration and capability of transatrial TMVI to treat mitral annular calcification and native mitral valve disease. Our results are favorable when compared with TMVI global registry data for transseptal or transapical approach. Elsevier 2021-08-10 /pmc/articles/PMC8691218/ /pubmed/34977731 http://dx.doi.org/10.1016/j.xjtc.2021.08.004 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Adult: Mitral Valve: Evolving Technology
Hamid, Umar Imran
Gregg, Anne
Ball, Peter
Owens, Colum
Manoharan, Ganesh
Spence, Mark S.
Jeganathan, Reuben
Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title_full Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title_fullStr Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title_full_unstemmed Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title_short Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
title_sort open transcatheter valve implantation for mitral annular calcification: one-year outcomes
topic Adult: Mitral Valve: Evolving Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691218/
https://www.ncbi.nlm.nih.gov/pubmed/34977731
http://dx.doi.org/10.1016/j.xjtc.2021.08.004
work_keys_str_mv AT hamidumarimran opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT gregganne opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT ballpeter opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT owenscolum opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT manoharanganesh opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT spencemarks opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes
AT jeganathanreuben opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes